Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic respiratory infectious disease COVID-19. However, clinical manifestations and outcomes differ significantly among COVID-19 patients, ranging from asymptomatic to extremely severe, and it remains unclear what drives these disparities. Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses. SARS-CoV-2 infection was associated with a marked increase in individual’s immune memory antibody repertoires linked to trajectories of disease severity from the longitudinal analysis also including anti-spike protein antibodies. By applying a machine-learning-based strategy, we developed a viral exposure signature predictive of COVID-19-related disease severity linked to patient survival. These results provide a basis for understanding the roles of memory B-cell repertoires in COVID-19-related symptoms as well as a predictive tool for monitoring its clinical severity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by grants from the Intramural Research Program of the Center for Cancer Research of the National Cancer Institute (grant ZIA BC 011951 to XWW), the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (grant AI001270-01 to LDN) and by Regione Lombardia, Italy (project Risposta immune in pazienti con COVID-19 e comorbidita to LI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Deidentified discarded blood samples and clinical information were obtained under protocol NP-4000 approved by Comitato Etico Provinciale, Brescia, Italy. Because deidentified samples were provided, no informed consent was used. The NIH IRB from OHSR office considered this study non human subject research and determined that this study is exempted from ethics oversight.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
NIAID-NCI COVID-19 Consortium:
Ottavia M. Delmonte4
Marshonna Forgues1
Hui Liu4
Helen F. Matthews (Laboratory of Immunology, NIAID, NIH)
Elana Shaw4
Michael A. Stack4
Sarah Weber (Section of Molecular Development of the Immune System, NIAID, NIH)
Yu Zhang4
Data Availability
Data will be made available upon request
